-+ 0.00%
-+ 0.00%
-+ 0.00%

Belite Bio files Japan NDA for tinlarebant under Sakigake designation for Stargardt disease type 1

PUBT·09/08/2026 10:00:44
Listen to the news
Belite Bio files Japan NDA for tinlarebant under Sakigake designation for Stargardt disease type 1
  • Belite Bio filed a Japan NDA with the MHLW for tinlarebant to treat Stargardt disease type 1 under the Sakigake pathway.
  • The FDA accepted the US NDA for priority review, setting a PDUFA target action date of Feb. 12, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080600PRIMZONEFULLFEED9822492) on September 08, 2026, and is solely responsible for the information contained therein.